search
Back to results

Synapse 3D With Intravascular Indocyanine Green

Primary Purpose

Non-small Cell Lung Cancer, Primary Neoplasm

Status
Recruiting
Phase
Phase 1
Locations
Canada
Study Type
Interventional
Intervention
Synapse 3D Lung Modelling
IC-Green (ICG)
Sponsored by
St. Joseph's Healthcare Hamilton
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Non-small Cell Lung Cancer focused on measuring Segmentectomy, Lung Cancer, Robotic Surgery, 3D Modelling, CT Imaging, Near-Infrared Fluorescence, IC-GREEN, Surgical Planning, Indocyanine Green, Early-Stage Lung Cancer, Surgical Mapping, Lung Preservation

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Tumour size <3 cm
  • Clinical Stage 1 Non-Small Cell Lung Cancer (NSCLC)
  • CT-imaging confirming that the tumour is confined to one broncho-pulmonary segment, rendering the patient a candidate for segmental resection.

Exclusion Criteria:

  • Hypersensitivity or allergy to ICG, sodium iodide, or iodine
  • Women who are currently pregnant or breastfeeding; or women of childbearing potential who are not currently taking adequate birth control.
  • Patients with clinical evidence of N1 or N2 disease on preoperative imaging
  • Pulmonary Function tests demonstrating Forced Expiratory Volume in 1s (FEV1) or diffusion capacity of the lung for carbon monoxide (DLCO) less than or equal to 30% of predicted.

Sites / Locations

  • St. Josephs Healthcare HamiltonRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Synapse 3D Lung Modelling + IC-GREEN Segmentectomy

Arm Description

Patients within this arm will undergo a high-resolution CT scan of the chest, which is required by Synapse 3D to create accurate 3D virtual model reconstructions. At the start of the operation, the 3D virtual model of the segmental pulmonary anatomy will be displayed on the da Vinci Robotic platform for operative planning. The model will be used as a guide to determine which vessels are involved in the segment and need to be removed. The surgeon will ligate the pulmonary vein and pulmonary artery of the broncho-pulmonary segment with the lung cancer nodule, isolating it from any blood supply, and mark the proposed segmental planes based on the 3D model. ICG will be prepared as a sterile solution (2.5 mg/10mL) for injection. After vascular ligation, an 8 mL bolus of ICG solution will be injected into the peripheral vein catheter, followed by a 10 mL saline solution bolus

Outcomes

Primary Outcome Measures

Segmental Resection Conversion Rate
Rate of conversions to lobectomy will be measured by collecting the proportion of conversions to lobectomy.
Number of Participants with Post Operative Complications
Post operative complications will be reported and measured using the Ottawa Thoracic Morbidity and Mortality Classification of (a) Adverse reactions to ICG dye at the time of surgery and (b) Perioperative complications through study completion.

Secondary Outcome Measures

Anatomical Accuracy of the 3D Lung Model
Anatomical accuracy will be evaluated using the criteria listed in points a-c. A score of 3/3 on these items will indicate success of anatomical accuracy Ex-vivo localization of lesions; Ex-vivo confirmation of tumor-free margins around lesion; Ex-vivo confirmation of adequate anatomical inter-segmental.
Surgeon Confidence
A pre-operative CT scan based, a pre-operative 3D reconstruction based and post segmental resection surgeon confidence score will be obtained on a scale of 1-5: 1 - not at all confident, 2 - somewhat confident, 3 - confident, 4 - very confident, 5 - extremely confident.
Operation Time
Length of time of the operation will be measured by collecting the time the patient entered the operating room until the time the patient left the operating room.
Conversion to Thoracotomy
Rate of conversion to thoracotomy will be measured by collecting the proportion of conversions to thoracotomy. Descriptive analysis of reasons for conversion will also be collected.
Chest Tube Duration
Duration the patient had chest tubes in situ will be measured by collecting the date of surgery and the date the chest tube was removed.
Length of Stay
Duration of hospital length of stay will be measured by collecting the data of admission and the date of discharge.
Estimated Blood Loss
Estimated blood loss will be measured at the time of operation by OR staff.

Full Information

First Posted
April 30, 2019
Last Updated
January 23, 2023
Sponsor
St. Joseph's Healthcare Hamilton
search

1. Study Identification

Unique Protocol Identification Number
NCT03953144
Brief Title
Synapse 3D With Intravascular Indocyanine Green
Official Title
Synapse 3D With Intravascular Indocyanine Green Fluorescence Mapping for Targeted Pulmonary Segmental Resection Trial: A Phase I Safety and Feasibility Trial
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 1, 2022 (Actual)
Primary Completion Date
September 30, 2023 (Anticipated)
Study Completion Date
December 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
St. Joseph's Healthcare Hamilton

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
With the advent of CT screening for lung cancer, an increasing number of NSCLCs are being detected at very early stages, and the demand for pulmonary segmentectomy is rising rapidly. As such, there is a need to develop new surgical techniques to facilitate minimally invasive pulmonary segmentectomy, as segmentectomy may provide a number of significant advantages over lobectomy for patients presenting with early-stage lung cancer, or for patients unable to undergo a full lobectomy due to existing comorbidities. This study will provide the first case series using preoperative 3D anatomical planning (Synapse 3D) added to ICG and NIF-guided robotic segmentectomy to date and will be the first reported use of Synapse 3D-guided targeted pulmonary segmental resection in Canada. As lung cancer is the most frequently fatal cancer in North America, many thousands of patients will be able to benefit from this operation every year.
Detailed Description
Lungs are made up of individual lobes. When a lung cancer tumour is found in one of these lobes, the surgeon often performs a Lobectomy. A Lobectomy is the surgery most commonly done to treat early-stage lung cancer and requires removal of an entire lobe of the lung, which removes a large amount of lung tissue For patients with small tumours saving as much healthy lung tissue as possible is important. Each lobe of the lung has smaller sections called segments. When a lung cancer is in one of these segments, it is possible to remove that segment, without removing the entire lobe. This surgery is called a Segmentectomy. Compared to a lobectomy, a segmentectomy saves a larger amount of healthy lung tissue. Research shows that a segmentectomy can result in less blood loss, shorter operation time, less days of having a chest tube, and a shorter hospital stay, compared to a lobectomy. With the advances in screening technology for lung cancer tumours, an increasing amount of very small lung cancer tumours are being found, and the demand for segmentectomy is increasing. A segmentectomy is a hard surgery to perform robotically because it is difficult to view the tissue lines that separate each segment within the lobe. As a result, it is difficult for the surgeon to see exactly which pieces of tissue should be removed in order to safely complete the segmentectomy. Because of these challenges, many patients having robotic surgery will have a lobectomy, even if a full lobectomy is not needed. In response to these challenges, our surgical group has developed the technique of using Near-Infrared Fluorescence (NIF) mapping with intravascular indocyanine green (ICG) dye injection. With the aid of an infrared camera the surgeon is able to see the segment within a lobe of lung after injection of the ICG dye, allowing for a more accurate segmentectomy. We recently reported a 60% success rate of segmental resections with the use of ICG and NIF-guided surgical resection. However, a limitation to this technique is that the segmental anatomy can only be seen during the operation and only after cutting the blood vessels. The introduction of 3D reconstruction and virtual modeling provides a new way to locate lesions accurately within a segment and plan the appropriate operation before the actual surgery occurs. Synapse 3D (Mississauga, Canada) is a 3D modelling technology that is capable of producing a detailed 3D virtual model of a patient's lung based on Computed Tomography (CT) scans. It has been shown to be safe and feasible in performing segmental pulmonary resections on a robotic platform. In this study, we propose a new operation that uses 3D anatomical planning before the surgery (Synapse 3D) and real-time NIF-mapping at the time of surgery using ICG dye, which we believe will greatly increase the likelihood of a successful segmentectomy. If this new operation is successful, it will help patients save more of their healthy lung tissue when they are undergoing surgery for lung cancer.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-small Cell Lung Cancer, Primary Neoplasm
Keywords
Segmentectomy, Lung Cancer, Robotic Surgery, 3D Modelling, CT Imaging, Near-Infrared Fluorescence, IC-GREEN, Surgical Planning, Indocyanine Green, Early-Stage Lung Cancer, Surgical Mapping, Lung Preservation

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Model Description
This study is a single centre, prospective clinical trial evaluating the safety and feasibility of adding 3D anatomical reconstructions and real-time intraoperative planning using Synapse 3D software added to NIF-guided targeted segmental resection. It is anticipated that 32 participants will be enrolled within a 1-year period. Enrollment will take place at St. Joseph's Healthcare Hamilton. All patients enrolled will be evaluated until their first scheduled follow-up appointment (within 30 days post-surgery).
Masking
None (Open Label)
Masking Description
Open Label, single-arm feasibility trial.
Allocation
N/A
Enrollment
32 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Synapse 3D Lung Modelling + IC-GREEN Segmentectomy
Arm Type
Experimental
Arm Description
Patients within this arm will undergo a high-resolution CT scan of the chest, which is required by Synapse 3D to create accurate 3D virtual model reconstructions. At the start of the operation, the 3D virtual model of the segmental pulmonary anatomy will be displayed on the da Vinci Robotic platform for operative planning. The model will be used as a guide to determine which vessels are involved in the segment and need to be removed. The surgeon will ligate the pulmonary vein and pulmonary artery of the broncho-pulmonary segment with the lung cancer nodule, isolating it from any blood supply, and mark the proposed segmental planes based on the 3D model. ICG will be prepared as a sterile solution (2.5 mg/10mL) for injection. After vascular ligation, an 8 mL bolus of ICG solution will be injected into the peripheral vein catheter, followed by a 10 mL saline solution bolus
Intervention Type
Device
Intervention Name(s)
Synapse 3D Lung Modelling
Intervention Description
The 3D virtual models provided by Synapse 3D will be made by experts in medical image analysis using the high-resolution CT scans. Patients will have 3D virtual reconstructions of their pulmonary anatomy with the target lesion created pre-operatively.
Intervention Type
Drug
Intervention Name(s)
IC-Green (ICG)
Other Intervention Name(s)
Indocyanine Green
Intervention Description
ICG will be prepared as a sterile solution (2.5 mg/10mL) for injection. After vascular ligation, a 6 to 8mL bolus of ICG solution will be injected into the peripheral vein catheter, followed by a 10mL saline solution bolus. The Firefly camera will then be used for the NIF imaging. It is expected that the entire lung, except the segment which was previously isolated from blood supply, will fluoresce within 30-40 seconds, exhibiting a green hue. The surgeon will perform the pulmonary resection and the resected 'dark' lung segment will be immediately evaluated by a pathologist, depending on the pathologist findings the operation may be concluded or the patient will receive a pulmonary lobectomy.
Primary Outcome Measure Information:
Title
Segmental Resection Conversion Rate
Description
Rate of conversions to lobectomy will be measured by collecting the proportion of conversions to lobectomy.
Time Frame
1 year
Title
Number of Participants with Post Operative Complications
Description
Post operative complications will be reported and measured using the Ottawa Thoracic Morbidity and Mortality Classification of (a) Adverse reactions to ICG dye at the time of surgery and (b) Perioperative complications through study completion.
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Anatomical Accuracy of the 3D Lung Model
Description
Anatomical accuracy will be evaluated using the criteria listed in points a-c. A score of 3/3 on these items will indicate success of anatomical accuracy Ex-vivo localization of lesions; Ex-vivo confirmation of tumor-free margins around lesion; Ex-vivo confirmation of adequate anatomical inter-segmental.
Time Frame
1 year
Title
Surgeon Confidence
Description
A pre-operative CT scan based, a pre-operative 3D reconstruction based and post segmental resection surgeon confidence score will be obtained on a scale of 1-5: 1 - not at all confident, 2 - somewhat confident, 3 - confident, 4 - very confident, 5 - extremely confident.
Time Frame
1 year
Title
Operation Time
Description
Length of time of the operation will be measured by collecting the time the patient entered the operating room until the time the patient left the operating room.
Time Frame
1 year
Title
Conversion to Thoracotomy
Description
Rate of conversion to thoracotomy will be measured by collecting the proportion of conversions to thoracotomy. Descriptive analysis of reasons for conversion will also be collected.
Time Frame
1 year
Title
Chest Tube Duration
Description
Duration the patient had chest tubes in situ will be measured by collecting the date of surgery and the date the chest tube was removed.
Time Frame
1 year
Title
Length of Stay
Description
Duration of hospital length of stay will be measured by collecting the data of admission and the date of discharge.
Time Frame
1 year
Title
Estimated Blood Loss
Description
Estimated blood loss will be measured at the time of operation by OR staff.
Time Frame
1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Tumour size <3 cm Clinical Stage 1 Non-Small Cell Lung Cancer (NSCLC) CT-imaging confirming that the tumour is confined to one broncho-pulmonary segment, rendering the patient a candidate for segmental resection. Exclusion Criteria: Hypersensitivity or allergy to ICG, sodium iodide, or iodine Women who are currently pregnant or breastfeeding; or women of childbearing potential who are not currently taking adequate birth control. Patients with clinical evidence of N1 or N2 disease on preoperative imaging Pulmonary Function tests demonstrating Forced Expiratory Volume in 1s (FEV1) or diffusion capacity of the lung for carbon monoxide (DLCO) less than or equal to 30% of predicted.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Peter R. A. Malik, BHSc (Honours)
Phone
905-522-1155
Ext
35096
Email
malikpr@mcmaster.ca
First Name & Middle Initial & Last Name or Official Title & Degree
Yogita S Patel, BSc
Phone
905-522-1155
Ext
35096
Email
patelys@mcmaster.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Waël C Hanna, MDCM, MBA, FRCSC
Organizational Affiliation
St. Joseph's Healthcare Hamilton / McMaster University
Official's Role
Principal Investigator
Facility Information:
Facility Name
St. Josephs Healthcare Hamilton
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8N 4A6
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yogita S Patel, BSc
Phone
905-522-1155
Ext
35096
Email
patelys@mcmaster.ca
First Name & Middle Initial & Last Name & Degree
Wael C. Hanna, MDCM, MBA, FRCSC

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
9104978
Citation
Landreneau RJ, Sugarbaker DJ, Mack MJ, Hazelrigg SR, Luketich JD, Fetterman L, Liptay MJ, Bartley S, Boley TM, Keenan RJ, Ferson PF, Weyant RJ, Naunheim KS. Wedge resection versus lobectomy for stage I (T1 N0 M0) non-small-cell lung cancer. J Thorac Cardiovasc Surg. 1997 Apr;113(4):691-8; discussion 698-700. doi: 10.1016/S0022-5223(97)70226-5.
Results Reference
background
PubMed Identifier
23628209
Citation
Zhao X, Qian L, Luo Q, Huang J. Segmentectomy as a safe and equally effective surgical option under complete video-assisted thoracic surgery for patients of stage I non-small cell lung cancer. J Cardiothorac Surg. 2013 Apr 29;8:116. doi: 10.1186/1749-8090-8-116.
Results Reference
background
PubMed Identifier
28740676
Citation
Bedetti B, Bertolaccini L, Rocco R, Schmidt J, Solli P, Scarci M. Segmentectomy versus lobectomy for stage I non-small cell lung cancer: a systematic review and meta-analysis. J Thorac Dis. 2017 Jun;9(6):1615-1623. doi: 10.21037/jtd.2017.05.79.
Results Reference
background
PubMed Identifier
29785286
Citation
Gossot D, Seguin-Givelet A. Anatomical variations and pitfalls to know during thoracoscopic segmentectomies. J Thorac Dis. 2018 Apr;10(Suppl 10):S1134-S1144. doi: 10.21037/jtd.2017.11.87.
Results Reference
background
PubMed Identifier
30803778
Citation
Mehta M, Patel YS, Yasufuku K, Waddell TK, Shargall Y, Fahim C, Hanna WC. Near-infrared mapping with indocyanine green is associated with an increase in oncological margin length in minimally invasive segmentectomy. J Thorac Cardiovasc Surg. 2019 May;157(5):2029-2035. doi: 10.1016/j.jtcvs.2018.12.099. Epub 2019 Jan 21.
Results Reference
background
PubMed Identifier
18703345
Citation
Fukuhara K, Akashi A, Nakane S, Tomita E. Preoperative assessment of the pulmonary artery by three-dimensional computed tomography before video-assisted thoracic surgery lobectomy. Eur J Cardiothorac Surg. 2008 Oct;34(4):875-7. doi: 10.1016/j.ejcts.2008.07.014. Epub 2008 Aug 15.
Results Reference
background
PubMed Identifier
29785294
Citation
Baste JM, Soldea V, Lachkar S, Rinieri P, Sarsam M, Bottet B, Peillon C. Development of a precision multimodal surgical navigation system for lung robotic segmentectomy. J Thorac Dis. 2018 Apr;10(Suppl 10):S1195-S1204. doi: 10.21037/jtd.2018.01.32.
Results Reference
background
PubMed Identifier
21256276
Citation
Ivanovic J, Al-Hussaini A, Al-Shehab D, Threader J, Villeneuve PJ, Ramsay T, Maziak DE, Gilbert S, Shamji FM, Sundaresan RS, Seely AJ. Evaluating the reliability and reproducibility of the Ottawa Thoracic Morbidity and Mortality classification system. Ann Thorac Surg. 2011 Feb;91(2):387-93. doi: 10.1016/j.athoracsur.2010.10.035.
Results Reference
background
PubMed Identifier
24680390
Citation
Pardolesi A, Veronesi G, Solli P, Spaggiari L. Use of indocyanine green to facilitate intersegmental plane identification during robotic anatomic segmentectomy. J Thorac Cardiovasc Surg. 2014 Aug;148(2):737-8. doi: 10.1016/j.jtcvs.2014.03.001. Epub 2014 Mar 5. No abstract available.
Results Reference
background

Learn more about this trial

Synapse 3D With Intravascular Indocyanine Green

We'll reach out to this number within 24 hrs